Nutritional support to accompany your weight management journey
Recent evidence from phase 2 clinical trials for MASH demonstrated that pharmacological agents based on GLP-1 receptor agonism are effective in improving disease activity, that is, steatohepatitis
Growing evidence links MASLD and sarcopenia with metabolic syndrome, and the components of metabolic syndrome strengthen this relationship, leading to progressive disease and poor prognosis
Other investigations may include assessment of renal function, blood glucose, and vitamin B12 levels
Researchers are continuing to study their effectiveness, absorption rates, and potential side effects compared to traditional GLP-1 injections
Experience the Huntington Harbour Laser Difference Dont let declining glutathione levels hold you back from feeling your best